Yunbing Wang

Yunbing Wang, Ph.D.
Professor, Sichuan University
yunbing.wang@scu.edu.cn
 
Biography: 

Professor Yunbing Wang is the Director of Chinese National Engineering Research Center for Bomaterials, Vice President of Chinese Society for Biomaterials, and Director of Engineering Research Center in Biomaterials of Sichuan University. 

Prof. Wang’s current research interest is in the area of advanced biomaterials and implantable medical device development for the treatment of cardiovascular disease, diabetes, cancer and eye disease, etc. 

Prof. Wang is an inventor of more than 200 US and international patents leading to several commercialized medical device products in the world. Before taking his current position, he worked at different medical device companies including Medtronic, Boston Scientific, Abbott and CooperVision, and worked as the technical leader and leading inventor of several products development, including fully bioresorbable stent for cardiovascular disease treatment and artificial pancreas device system for diabetes treatment. 

Topic title:

Research Frontier of Transcatheter Heart Valve and Stent

Abstract:

Minimally invasive interventional heart valves and stents are two major products in the development of various cardiovascular materials and devices. At present, the research of therapeutic devices for heart valve diseases focuses on the development of minimally invasive interventional heart valve materials with strong ability of pre-package, anti-calcification, anti-fatigue, and anti-tearing. We worked with company together to develop transcatheter aortic valve product and got it approved in China in 2017, which has been used in more than 100 hospitals.

In the field of minimally invasive interventional stent, in addition to the continuous optimization of traditional drug coated metallic stent, bioresorbable stent is the leading edge of its development. After the completion of vascular repair, such stents can be gradually absorbed without affecting the future reinterventional therapy, which could reduce the long-term retention of stents and the time of dual antiplatelet therapy. In recent years, great breakthroughs have been made in the research and preparation of bioresorbable stents.
Fig 1. Transcatheter Heart Valve development


Fig 2. Bioresorbable stent development
Key Dates
Key Dates
Abstract continue accepting
Deadline for Submission of Abstract:

October 31, 2019

Notification of abstract acceptance:
November 15, 2019




Registration